Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DFP Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DFP Holdings's regulatory disclosures and financial reporting.
Oncology Institute, Inc. major shareholder Jorey Chernett reported an open-market purchase of 125,000 shares of common stock at a weighted average price of $3.11 per share. After this buy, Chernett directly owns 10,401,929 common shares. The purchase was executed in multiple trades between $3.04 and $3.15 per share.
Oncology Institute, Inc. ten percent owner Jorey Chernett bought 25,000 shares of Common Stock in an open‑market transaction. The weighted average purchase price was about $3.35 per share, with individual trades between $3.33 and $3.35.
After this purchase, Chernett directly owns 10,276,929 Oncology Institute shares.
Oncology Institute, Inc. director Kimberly Jo Tzoumakas filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. This filing does not report any transactions or derivative positions and serves only to establish her reporting status with the company.
Oncology Institute, Inc. Chief Executive Officer Daniel Virnich reported an administrative stock transaction linked to restricted stock unit (RSU) vesting. On March 17, 2026, the issuer executed a sale of 11,834 shares of common stock at $3.59 per share to cover tax liabilities from the RSU vesting. Following this tax-related sale, Virnich’s directly held position is 1,788,150 common shares, indicating he retains a large equity stake after the routine transaction.
Oncology Institute, Inc. Chief Financial Officer Robert Ross Carter reported an "other" type transaction involving 1,314 shares of common stock at $3.59 per share on March 17, 2026. According to the disclosure, the issuer executed the sale to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on that date, making this a tax-related, non-discretionary event rather than an open-market trade. Following the transaction, Carter directly held 233,811 shares of common stock.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an administrative share transaction involving 3,420 shares of common stock on March 17, 2026 at $3.59 per share. According to the footnote, the issuer executed this sale to cover tax liabilities from the vesting of a restricted stock unit (RSU) award on the same date.
Following the transaction, Podnos directly holds 234,510 common shares. Because the sale was made to satisfy tax obligations tied to compensation vesting, it reflects a routine, non-discretionary event rather than an open-market investment decision.
Oncology Institute, Inc. disclosed that 10% owner Jorey Chernett made three open-market purchases of Common Stock, totaling 398,985 shares, at reported weighted average prices of about $2.92–$3.42 per share. Following these transactions, he directly owns 10,251,929 shares. The footnotes explain that each reported price is a weighted average for multiple trades within specified intraday price ranges.
Oncology Institute, Inc. filed an initial insider ownership report showing that major shareholder Jorey Chernett beneficially owns 9,852,944 shares of the company’s common stock. These shares are reported as held directly, reflecting an existing position rather than a new purchase or sale.
Oncology Institute, Inc. amendment to a Schedule 13G reports that Jorey Chernett beneficially owned 10,115,944 shares of Common Stock as of the close of business on March 13, 2026, representing 10.23% of outstanding shares. The filing cites 98,839,144 Shares outstanding as of March 5, 2026 per the company’s Annual Report on Form 10-K filed March 12, 2026. The cover page shows the Reporting Person has sole voting and dispositive power over the 10,115,944 shares. The amendment is signed by Jorey Chernett on March 16, 2026.
The Oncology Institute, Inc. filed a current report to make investors aware of a new investor presentation. The company plans to use this presentation in meetings with investors to explain its business and outlook. The presentation is included as Exhibit 99.1 and is dated March 13, 2026.
The material in the investor presentation is being furnished under Regulation FD, which means it is provided for information purposes and is not treated as filed financial statements. The company’s common stock trades on the Nasdaq Stock Market under the symbol TOI, and its redeemable warrants trade under the symbol TOIIW.